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Abstract: Axonal regeneration does not occur easily after an adult central nervous system (CNS) 
injury. Various attempts have partially succeeded in promoting axonal regeneration after the 
spinal cord injury (SCI). Interestingly, several recent therapeutic concepts have emerged from 
or been tightly linked to the researches on brain development. In a developing brain, remarkable 
and dynamic axonal elongation and sprouting occur even after the injury; this ﬁ  nding is essential 
to the development of a therapy for SCI. In this review, we overview the revealed mechanism 
of axonal tract formation and plasticity in the developing brain and compare the differences 
between a developing brain and a lesion site in an adult brain. One of the differences is that mature 
glial cells participate in the repair process in the case of adult injuries. Interestingly, these cells 
express inhibitory molecules that impede axonal regeneration such as myelin-associated proteins 
and the repulsive guidance molecules found originally in the developing brain for navigating 
axons to speciﬁ  c routes. Some reports have clearly elucidated that any treatment designed to 
suppress these inhibitory cues is beneﬁ  cial for promoting regeneration and plasticity after an 
injury. Thus, understanding the developmental process will provide us with an important clue 
for designing therapeutic strategies for recovery from SCI.
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Introduction
Axonal regeneration is a fundamental step in the process of recovering from spinal cord 
injury (SCI). However, the axons in the adult central nervous system (CNS) cannot 
regenerate easily, which primarily causes the lack of adequate restorative therapy for 
the SCI so far. Several attempts have been made to promote regeneration, and some 
advances have been obtained. Importantly, these attempts appear to be the applica-
tions of certain extensively revealed mechanisms of brain development. Although the 
axons cannot regenerate easily in an adult brain, in the developing brain, differentiating 
neurons elongate the axons easily to very distal areas; this information is of utmost 
importance and is required to be considered post SCI. What is the difference between 
the ability of elongating the axons in the adult and developing brain? Understanding the 
mechanism of tremendous axonal elongation and navigation during development and 
the differences between the environments of adult and developing CNS has provided us 
with important clues for succeeding in regenerating axons after brain injuries. Although 
several allusions for the therapy have also been brought by the comparison between 
the peripheral nervous system (PNS) and the CNS because axons can regenerate 
in the former system but not in the latter, in this review, we will focus on and compare 
the differences between the adult and developing brain. We have brieﬂ  y summarized 
the differences discussed in this review in Figure 1C. From this view, we can consider 
how the recent concepts and strategies for regenerating axons in the adult CNS have Biologics: Targets & Therapy 2008:2(2) 254
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emerged and can be developed. Although several excellent 
reviews have yet described the importance of the relation of 
regenerative therapy with the developmental mechanisms 
(Schwab and Bartholdi 1996; Harel and Strittmatter 2006), 
we will overview the whole aspects of its relations as much 
as possible with recent reports, and will emphasize that col-
laboration with developmental and clinical neuroscience is 
more needed.
Axonal regeneration 
in the developing brain
Many earlier reports indicate that the axons in the early 
postnatal spinal cord can regenerate more easily after an 
injury compared to those in an adult (Figure 1: Berstein 
and Stelzner 1983; Bates and Stelzner 1993; Firkins et al 
1993). This ﬁ  nding provides two main important sugges-
tions. First, early brain tissue possesses favorable factors 
and environment for axonal growth, and the second, younger 
neurons themselves have a greater capacity for outgrowth 
than adult neurons. The ﬁ  rst suggestion is a well-accepted 
concept, and many inhibitory factors in the adult brain have 
been identiﬁ  ed up till now. We have reviewed these factors 
in the coming chapters; however, the important point is that 
understanding the favorable environment for axonal growth 
in the developing brain may generate a new approach in the 
designing of a therapy for SCI. Indeed, in many classical 
experiments, embryonic spinal cord was transplanted in the 
lesion site of the postnatal and adult spinal cord (Bregman 
et al 1989, 1993; Iwashita et al 1994). In the early postnatal 
case, injured axons demonstrated immense regeneration pass-
ing through the transplanted embryonic tissue. In the adult 
case, axons could regenerate slightly but not dramatically. 
This also supports the abovementioned two suggestions, 




(Netrin, Sema, Ephrin, Slit, RGM)
inhibitory
(Sema, Ephrin, RGM)
treatment of specific antibody
or inhibitor
transplantation of Scehwann cell, OEG,
or others































treatmet of chondroitinase ABC
transplantation of immature astrocytes?
activate to accelerate repair process?
treatmet of specefic antibody
developing brain adult SCI strategies
Figure 1 Comparison between the environments of a developing brain and an adult brain after SCI. A: Axons (blue line; in this case, CST) projected up to a long distance 
through a speciﬁ  c route. Even after the injury (red), axons can regenerate more extensively than in adults. Compensatory sprouting also occurs with high plastic ability (orange 
arrow). B: In the adult brain, axons (green line; in this case, CST) cannot regenerate after the injury (red), but compensatory sprouting occur in the rostral positions (orange 
arrows); however, the extent to which this occurs is not greater than that in the developing brain. C: Different components and their properties involved in the developing and 
adult brains after the SCI. Each function is represented as the role toward axonal outgrowth (regeneration) and sprouting (plasticity). The properties of the components are 
presented within the parentheses. The strategies for the therapy targeting each component are represented in the right column. The details can be found in the text.Biologics: Targets & Therapy 2008:2(2) 255
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neurons may possess a greater capacity of growth. It may 
be clear that younger neurons or certain types of neurons 
possess a much higher ability of elongating axons compared 
to other neurons, as suggested by the reports indicating that 
transplanted embryonic cortical neurons in the injured cor-
tex can extend the axons even through the adult spinal cord 
(Gaillard et al 2007), and that neurons in different mouse 
strains have different regenerative abilities after SCI (Dimou 
et al 2006). However, many of the recent approaches have 
partially succeeded in regenerating axons by suppressing the 
inhibitory cues in the adult brain, suggesting that even the 
adult neurons have the ability to re-elongate axons. From this 
view, generating a favorable environment for axonal growth 
in the injured site should be one of the important goals for 
establishing therapeutic interventions.
Axonal network formation 
by guidance molecules 
in the developing brain
We should ﬁ  rst understand how the complicated and precise 
axonal network is formed in the developing brain. During 
development, several steps are required to form a complex 
structure and for the functioning of the brain. First, undif-
ferentiating neural stem cells or progenitor cells proliferate 
extensively around the ventricle called ventricular zone to 
reserve a large number of neurons and glial cells for the 
future adult brain. Next, some of these cells start migrating to 
speciﬁ  c areas and differentiating into neurons. After reaching 
the ﬁ  nal position, the neurons start projecting the axons to the 
target area. In many cases, the axons are facilitated to pass 
through speciﬁ  c routes and targeted to speciﬁ  c areas. This 
process is very surprising because this navigation is quite 
precise, and in some cases, the neurons project the axons 
to a great distance from the cell bodies. Since 1990’s, the 
mechanism of this precise navigation has been revealed by 
various studies identifying the axonal guidance molecules. 
Netrin, Ephrin, Semaphorin, and Slit are the representative 
guidance molecules (for review Huber et al 2003). In vitro 
culture system and the analyses from knockout mice have 
clearly revealed that these molecules have an important role 
in navigating axons in the developing brain. For example, 
corticospinal tract (CST), the main tract connecting the sen-
sorimotor cortex to the spinal cord for regulating the motor 
function (Figure 1), is also navigated by these molecules. 
In the ﬁ  rst step, Sema3A expressed in the upper layers of 
the cortex repulses the axons of neurons in the deeper layer 
(layer V in the future) to the deeper white matter (Polleux 
et al 1998, 2000). Slit2 then repulses the axons after passing 
the internal capsule, for projecting the speciﬁ  c route into the 
cerebral peduncle (Bagri et al 2002). After having passed 
the cerebral peduncle, most of the ﬁ  bers cross the midline 
and go through to the contralateral side. It is indicated that 
Netrin and its receptors, Dcc and Unc5H3 contribute to this 
decussation (Finger et al 2002). While passing the spinal 
cord, Ephrin-B3 repulses the CST not to cross the midline 
(Kullander et al 2001; Yokoyama et al 2001).
Recent reports have demonstrated other important 
molecules responsible for guiding axons, morphogens. 
Morphogens – such as Sonic hedgehog (Shh), Fibroblast 
growth factor (Fgf), Bone morphogenetic protein (Bmp), and 
Wnts – are the signaling molecules that diffuse and establish 
a gradient in the embryonic tissues. This gradient signal 
plays a crucial role in arealizing the tissues by changing the 
cells from single type to heterogeneous populations. These 
molecules play a similar role in the developing CNS. The 
famous example is that of the developing spinal cord in which 
Shh, which is expressed in the most ventral place called ﬂ  oor 
plate, is diffused dorsally and establishes a gradient concen-
tration. As a result, several clusters of neuronal populations 
are generated in the ventral spinal cord depending on the 
concentration of Shh (Jacob and Briscoe 2003). Intriguingly, 
recent papers have indicated that these morphogens regulate 
not only the speciﬁ  cation of tissue areas and cell population, 
but also navigate the axons (for review Charron and Tessier-
Lavigne 2005). Again, CST passes through the spinal cord up 
to a long distance mainly in the ﬁ  rst postnatal week in rodents 
(Gianino et al 1999; Joosten and Bär 1999). Interestingly, 
developing CST expresses Ryk, one of the Wnts receptors, 
and is pushed down by Wnts signals in the spinal cord after 
decussation (Liu et al 2005). Wnt1 and 5a are expressed in 
a rostral to caudal gradient that repulses the CST into lower 
levels. Thus, CST can be guided for a long distance to the 
ﬁ  nal targets by Wnts signaling.
One ultimate strategy for facilitating deﬁ  nite regeneration 
after the SCI may be to reconstruct these guidance cues in 
precise positions spatially and temporally like in the develop-
ing brain. Joosten et al (1995) showed that injured CST in 
adult rats could regenerate by the local application of cervical 
spinal cord extracts which were harvested at the time that 
developing CST axons reached this spinal cord level. On 
the other hand, the injured axons could not regenerate when 
spinal cord extracts were harvested at younger or older age. 
This data implied that speciﬁ  cally organized expression of 
guidance molecules seen in the development is also optimal 
for regeneration. It is known, however, that some of these 
guidance molecules are still expressed in the adult developed Biologics: Targets & Therapy 2008:2(2) 256
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brain in a different manner or are abnormally re-expressed at 
the lesion site. This appears to make the precise reconstruc-
tion of guidance cues difﬁ  cult. In addition, some of these 
molecules are reported to suppress the regeneration of injured 
axons. Alternatively, recent researches have partly succeeded 
in promoting regeneration by suppressing the expression of 
these guidance molecules. We will focus on this issue in the 
later chapters.
Guiding cells that facilitate 
axonal network formation 
in the developing brain 
and their transplantation
Besides the axon guidance molecules, certain types of 
speciﬁ  c guiding cells navigate the axons in the develop-
ing brain. These cells were reported earlier as “guidepost 
cells” in the embryonic limb bud of grasshopper (Bentley 
and Caudy 1983), and in the following papers, several other 
types of navigating cells were identiﬁ  ed in the corpus cal-
losum (Silver and Ogawa 1983; Shu and Richards 2001), 
olfactory tract (Sato et al 1998), and thalamocortical axons 
(López-Bendito et al 2006) of the developing rodent brain. 
Although the existence of guiding cells in the developing 
CST is also speculated from the observation of immature 
astrocytes discovered in the route of CST in early postnatal 
days (Joosten and Gribnau 1989), unfortunately, there are no 
clear evidences regarding their role in guiding axons.
As developmentally, early brain tissues possess a favor-
able environment for axonal growth, implanting fetal nerve 
tissue may be a simple way of promoting regeneration after 
SCI. However, obtaining this tissue is extremely difﬁ  cult, 
thus rendering its implantation for clinical therapy rather 
questionable. The next strategy is to transplant guiding 
cells speciﬁ  c to the axons in the spinal cord; however, as 
mentioned earlier, speciﬁ  c guiding cells for the CST or 
other axons in the spinal cord have not been identiﬁ  ed yet. 
Hence, the ongoing approach is to transplant guiding or 
supportive cells that can be obtained from other parts of 
the body. Historically, two types of cell have mainly been 
attempted for conducting transplantation: the peripheral 
nerve (Schwann cells) (Richardson et al 1980; David and 
Aguayo 1981; Takami et al 2002) and olfactory ensheathing 
glial cells (OEG) (Li et al 1997; Ramón-Cueto et al 1998). 
These approaches were not designed from the mechanisms 
of developmental processes; rather, they were developed 
from the mechanism of regeneration and axonal outgrowth 
in the adult brain. Axons of PNS can regenerate more easily 
than those of CNS, raising the possibility that peripheral 
nerves or Schwann cells act as favorable substrates for 
axonal growth. OEGs are the specialized glial cells ensheath-
ing olfactory axons of neurosensory cells in the olfactory 
epithelium. Neurosensory cells (and their axons, olfactory 
axons) are continuously replaced and newly formed in the 
adult, suggesting that OEGs support axonal outgrowth. 
These transplanted cells bridge the lesion site after SCI and, 
to a certain extent, effect regeneration and functional recov-
ery. These experiments may provide us a new insight in to 
establishing therapeutic methods from the basic research on 
brain development: discoveries and identiﬁ  cation of guiding 
cells in the developing brain may open a new strategy to 
promote regeneration.
Distinct tissue responses in young 
and adult injured CNS: the role 
of glial cells
One of the points of differences between adult and developing 
brain is that adult CNS includes not only neurons but also a 
large number of matured glial cells. These cells are clearly 
activated in the injured site to repair the tissue, which appears 
to affect the outgrowth of injured axons.
Astrocytes are the cells that are activated after the injury 
and form a glial scar to repair the injured tissue. Glial scar 
formation is an important process for tissue repair. Condi-
tional and selective ablation of activated astrocytes after SCI 
delays the repair process and caused motor deﬁ  cits (Faulkner 
et al 2004). Conditional ablation of astrocytic activation 
using Stat3 conditional knockout model also diminishes the 
recovery (Okada et al 2006). These reports indicate that a 
glial scar plays an important role in tissue repair by protecting 
the neighboring intact tissues from excessive degeneration, 
inﬂ  ammation, demyelination, etc. Unfortunately, although 
the glial scar is a key contributor to repair, it simultaneously 
inhibits axonal regeneration (Rudge and Silver 1990). An 
important factor that suppresses the regeneration expressed 
by astrocytes is chondroitin sulfate proteoglycans (CSPGs) 
(Mckeon et al 1991; Jones et al 2003; Tang et al 2003). 
CSPGs are glycoproteins within extracellular matrices that 
function as barriers that inhibit the penetration of regenerating 
axons into the lesion sites. By either treating chodroitinase 
ABC, which is the bacterial enzyme that digests CSPGs, or 
by using transgenic mice that express chodroitinase ABC 
in astrocytes, it was possible to promote regeneration after 
SCI (Bradbury et al 2002; Cafferty et al 2007); although, 
functional recovery was not achieved in transgenic mice. Biologics: Targets & Therapy 2008:2(2) 257
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In the developing brain, astrocytes are generated from neural 
progenitor cells in the later period of development compared 
with neurons (Temple 2001). Thus, astrocytic responses do 
not occur in early embryonic brain injury (Ueno et al 2006). 
SCI in early postnatal days activates astrocytes but no more 
remarkably than in adults (Barrett et al 1984; Firkins et al 
1993) possibly due to the lower number of astrocytes and 
lesser extent of maturation. Interestingly, although CSPGs 
are basically considered as barriers to axonal elongation in 
the developing brain (Snow et al 1990; Katoh-Semba et al 
1995), they are not upregulated remarkably in the young 
reactive astrocytes after an injury (Mckeon et al 1991; Dow 
et al 1994). It may imply that axons in a younger brain can 
regenerate easily due to the lack of inhibitory factors from 
activated astrocytes. Moreover, others reported that reactive 
astrocytes in the younger brains could be permissive for or 
promote axonal growth (Rudge and Silbver 1990; Bähr et al 
1995). This suggests that there may be different types of 
astrocytes, particularly, an inhibitory and permissive type 
for axonal growth as indicated even in the amphibian which 
has a greater potential for regeneration (Reier 1979; Singer 
et al 1979). The permissive type also looks like a similar 
phenotype as seen in several regions of the developing brain 
as guiding cells (see previous chapter). Thus, understanding 
the mechanism of astroglial activation into different types 
and implanting supportive astrocytes into the lesion may 
establish a new approach to promote axonal outgrowth 
(Davies et al 2006).
Although, the reason for which scar formation is required 
to block regeneration is not clear, at least, the most important 
role of the scar should be ﬁ  nishing and enclosing the repairing 
(inﬂ  ammatory) response to protect from neighboring intact 
CNS tissue. Thus, scar response should not be eliminated 
from the list of possible strategies that can be considered 
for the therapy. Instead, because scar inhibits the outgrowth 
of axons, completing the repair process speedily and com-
pacting the scar to as small as possible, or deleting speciﬁ  c 
molecules that suppresses regeneration but not scar forma-
tion, should be the considered approach.
Oligodendrocytes are the glial cells that are involved 
in myelination. It is widely accepted that these cells (or 
its components and debris) also inhibit axonal regenera-
tion post SCI. Earlier experiments performed by Schwab’s 
group revealed that in the rats in which oligodendrocytes 
(and myelin) are deleted, axonal regeneration after SCI 
is promoted more than in control rats (Savio and Schwab 
1990). Subsequently, they generated a monoclonal antibody 
known as IN-1 that recognizes myelin-associated inhibitory 
proteins, and revealed that treatment using this antibody 
promotes axonal regeneration (Schnell and Schwab 1990; 
Bregman et al 1995). Then, Nogo was identiﬁ  ed as the 
inhibitory protein that is recognized by IN-1 (Chen et al 
2000; GrandPré et al 2000; Prinjha et al 2000). Myelin-
associated glycoprotein (MAG) (Mukhopadhyay et al 1994; 
McKerracher et al 1994), and oligodendrocyte myelin pro-
tein (OMgp) (Kottis et al 2002; Wang et al 2002) were also 
identiﬁ  ed as the inhibitory proteins for axonal outgrowth. 
Surprisingly, all of these three inhibitory proteins exert their 
inhibitory function through one common receptor, Nogo-66 
receptor (NgR) (Fournier et al 2001; Domeniconi et al 2002; 
Liu et al 2002; Wang et al 2002) and its receptor complex 
p75 (Wang et al 2002; Wong et al 2002; Yamashita et al 
2002), Lingo-1 (Mi et al 2004), and TROY (Park et al 2005; 
Shao et al 2005) (for review, Yamashita et al 2005). Exten-
sive studies using Nogo antibody (Schnell and Schwab 1990; 
Bregman et al 1995) and Nogo knockout mice (Kim et al 
2003; Simonen et al 2003) and NgR (Kim et al 2004) have 
demonstrated that this is one of the critical factors inhibiting 
regeneration in SCI; although, several reports were unable 
to prove similar roles of Nogo and NgR as inhibitors (Zheng 
et al 2003, 2005). Similarly, MAG (Bartsch et al 1995), p75 
(Song et al 2004) deﬁ  cient mice do not undergo regeneration 
after SCI, but treatment using Lingo-1 antagonist promotes 
axonal sprouting (Ji et al 2006). Several controversial results 
regarding the role of myelin-associated proteins in regenera-
tion suggest that the inhibitory cues may affect the injured 
axons through more varieties of molecules and through 
complicated mechanisms.
Myelination starts later in CNS development after P14 
in the spinal cord of the rodents (Schwab and Schnell 1989; 
Joosten et al 1989; Hsu et al 2006). This may also imply 
that the strong capacity of regeneration in younger animals 
is achieved due to lesser amounts of myelin components, 
although Nogo is expressed early in postnatal period by 
neurons (Huber et al 2002). Interestingly, less amount of 
myelin can also enable the developing axons to display the 
plastic changes (plasticity) during the early postnatal period 
for learning and adapting to their external environment. This 
fact could also lead to understanding the mechanism that 
promotes plasticity after an adult CNS injury. Indeed, some 
studies succeeded in promoting plasticity after the injury by 
modifying myelin-components. We will discuss this issue 
in the next section.
Microglia is the last glial cell that is believed to be 
originated from mesenchymal lineage (monocyte or myeloid) 
(Chan et al 2007), which is different from other glial cells that Biologics: Targets & Therapy 2008:2(2) 258
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are generated from neural progenitor cells (Temple 2001). 
One interesting aspect regarding microglia is that this cell has 
different phases or types that are beneﬁ  cial and detrimental 
for axons. One direct evidence that microglia is an inhibitory 
factor for regeneration is that treatment using minocycline, 
an inhibitor of activation of microglia, promotes recovery by 
decreasing the dieback of CST and cell death of oligodendro-
cytes (Stirling et al 2004; Festoff et al 2006; Yune et al 2007). 
Depletion of hematogenous macrophages also promotes 
partial recovery (Popovich et al 1999). Since minocycline 
has an additional neuroprotective effect (Yong et al 2004), a 
selective ablation of microglial cells using transgenic mice 
(Lalancette-Hébert et al 2007) may provide us with more 
convincing results regarding the actual role of microglia in 
SCI. The beneﬁ  cial aspects of these cells are suggested from 
the fact that coculturing microglia with neurons can promote 
the extension of neurites (Nakajima et al 1989; Chamak et al 
1994; Bouhy et al 2006). Indeed, microglia express neuro-
trophic factors (Elkabes et al 1996; Dougherty et al 2000). 
One report suggested that later activation of microglial cells 
in vivo by treatment of GM-CSF after SCI facilitates regener-
ation possibly due to BDNF expression by microglia (Bouhy 
et al 2006). Some other studies also succeeded in promoting 
recovery by transplanting microglia/macrophages (Prewitt 
et al 1997; Rabchevsky and Streit 1997). Another beneﬁ  cial 
role of microglia may be phagocytosis. As mentioned above, 
myelin-related protein is one of the key factors that inhibit 
regeneration. Microglia can phagocytose the myelin debris 
after CNS injury but not speedily and sufﬁ  ciently (George 
and Grifﬁ  n 1994; Buss and Schwab 2003). Thus, promoting 
the phagocytic ability may be one of the strategies that can be 
employed for therapy (Vallières et al 2006). Transplantation 
of macrophages that are prestimulated by peripheral nerves 
(myelin components) into injured site promotes the recovery 
of motor function (Rapalino et al 1998). Although it is not 
clear whether this beneﬁ  cial effect is due to the enhancement 
of phagocytic ability, one can deduce that in some way, an 
appropriate activation of microglia/macrophage targeted to 
autologous tissue (possibly myelin) is protective and effec-
tive in repair and regeneration (for review, Schwartz et al 
2006). In the developing brain, microglia inﬁ  ltrate into the 
CNS around E10 in rodents and are believed to play a role in 
engulﬁ  ng the dying apoptotic cells (Ashwell 1991). Interest-
ingly, microglial cells express neurotrophic factors even in 
the developing brain (Elkabes et al 1996), and it is assumed 
that these cells may have some role to play in axonal growth 
(Chamak et al 1994; Streit 2001), although a direct in vivo 
evidence is deﬁ  cient. In this case, understanding the role of 
microglia in the injured brain may offer an important clue 
regarding its role in development.
Plasticity in development, and adult 
brain injuries
It is known that after SCI, compensatory axonal sprouting 
occurs in the upper level of the lesion (Figure 1; Aoki et al 
1986; Li et al 1994; Weidner et al 2001; Fouad et al 2001). 
For a long time, the reason behind the occurrence of slight 
functional recovery, unless spinal axons regenerate, was 
unclear; however, Bareyre et al suggested that the new 
sprouting axons in the upper level establish a new contact 
with the intraspinal interneurons and form a new neural 
circuit that may contribute to partial recovery (Bareyre 
et al 2004). Interestingly, the temporal pattern of the newly 
generated sprouting appears to be signiﬁ  cantly similar to the 
developmental process of CST. As described above, axons in 
the CST are elongated in early postnatal life, and after some 
“waiting period” (approximately 3 days), passing axons start 
establishing collaterals; in other words, they begin sprouting 
(O’Leary and Terashima 1988; Gianino et al 1999; Joosten 
and Bär 1999). Thus, an understanding of the mechanism 
of collateral formation in the developing brain will lead us 
to a new approach for promoting sprouting that may lead 
to functional recovery after SCI. In the developing brain, 
axonal collateral formation appears to be initiated by diffus-
ible factors that emanate from their targets (Sato et al 1994; 
Joosten et al 1994). Although the cues that induce collateral 
formation in the spinal cord are unidentiﬁ  ed, a potential cue 
may be neurotrophic factors. NT-3 and BDNF are known to 
promote axonal branching in a variety of neurons. Indeed, 
NT-3 enhances developmental sprouting in the spinal cord, 
and also in the injured adult spinal cord (Schnell et al 1994; 
Grill et al 1997; Zhou et al 2003). Although some recent 
papers reveal contrasting results on NT-3, and propound 
instead that providing BDNF treatment to the cell body of 
CST promotes sprouting (Hiebert et al 2002; Hagg et al 2005; 
Vavrek et al 2006).
Interestingly, similar factors appear to be used for con-
trolling the developmental plasticity and plasticity after adult 
brain injury. Neural activity is the ﬁ  rst factor that inﬂ  uences 
the plastic changes. Developing visual cortex is one of the 
extensively studied areas regarding plasticity in development. 
Neural inputs from both eyes through the thalamus compete 
with each other in the developing visual cortex through neural 
activity. This competition normally forms speciﬁ  c ocular 
dominance columns in the visual cortex that respond to 
alternative eyes. Intriguingly, monocular deprivation during Biologics: Targets & Therapy 2008:2(2) 259
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the critical period, which is the window period during early 
postnatal days when plastic changes can occur, shifts the 
response of neurons in both columns toward the dominantly 
activated input from the opened eye (for review, Hensch 
2005). Thus, neural activity appears to be the ﬁ  rst step in 
inducing plasticity. In the case of SCI, many reports have 
indicated that rehabilitation – such as locomotor training 
and environmental enrichment, which supposedly enhance 
neural activity – promotes functional recovery in rodents 
(Lankhorst et al 2001; Van Meeteren et al 2003; Hutchinson 
et al 2004; Engesser-Cesar et al 2007). The mechanisms that 
improve function after rehabilitation are not fully understood; 
however, neural plasticity must be involved.
Neurotrophin is the next factor involved in plasticity. In 
the developing visual cortex, excess treatment or removal 
of BDNF, NT-4/5 prevents or delays ocular dominance 
formation (Cabelli et al 1995, 1997), and focal injection of 
NT-4/5 prevents the plastic shift in the visual cortex (Riddle 
et al 1995). This implies that axons from each eye compete 
with each other through limited amount of neurotrophins 
in an activity-dependent manner, and only the ones that 
can receive neurotrophic factors are stabilized. In the SCI, 
neurotrophic factors appear to enhance plastic changes via 
sprouting, as mentioned above. Thus, the precise treatment 
using neurotrophic factors and stimulation of neural activity 
(it is related to good rehabilitation strategies) should be one 
of the key strategies to enhance plasticity after SCI.
The last factor contributing to plasticity is inhibitory mol-
ecules. The increasing number of inhibitory factors during 
postnatal development appears to terminate or decrease the 
overall plasticity of neural connections. CSPGs that inhibit 
regeneration after SCI are one of the inhibitory factors that 
also decrease plasticity through the developing brain. CSPGs 
organize a perineuronal net as the extracellular matrix. 
Treatment using chondroitinase ABC degrades CSPGs and 
reactivates the plasticity toward monocular deprivation in 
the adult visual cortex (Pizzorusso et al 2002). Interestingly, 
increasing myelin formation also appears to terminate the 
plastic changes in the visual cortex of younger brain. It is 
reported that the critical period is delayed in the visual cortex 
of NgR deﬁ  cient mice (McGee et al 2005). As observed in 
younger animals, myelin components also inhibit plastic-
ity after adult brain injury. For example, in Nogo−/− and 
NgR−/− mice, sprouting (plasticity) of axons was promoted 
after CNS injury (Lee et al 2004; Cafferty and Strittmatter 
2006), and blocking NgR signals also enhanced sprouting 
rostral to the lesion site after SCI (Li et al 2004, 2005; Li 
and Strittmatter 2003).
In conclusion, all these instances suggest that plasticity of 
axons in the developing brain and adult brain after the injury 
appear to involve similar mechanisms. Thus, understanding 
the mechanism of plasticity during development will offer 
an important clue for developing a new therapeutic strategy 
for SCI by promoting plasticity.
Strategy for therapy: insights 
from guidance molecules
The last insights obtained from the researches on development 
are that a number of axonal guidance molecules guiding 
axons during development are re-expressed by the glial and 
inﬂ  ammatory cells after the injury or continuously expressed 
in adult CNS cells. By now, Netrin1 (Wehrle et al 2005), 
EphA4 (Goldshmit et al 2004), EphB2 (Bundesen et al 
2003), Sema3, 7a (De Winter et al 2002; Pasterkamp et al 
2003), and Slit1, 3 (Wehrle et al 2005) have been revealed 
to be expressed in the lesion site of SCI. Although these 
molecules have various roles in the repair process, such as 
activation of astrocytes (EphA4; Goldshmit et al 2004), scar 
formation (EphB2; Bundesen et al 2003), and migration of 
adult progenitor cells (Netrin1; Petit et al 2007), there are no 
doubts that some of these molecules also affect the outgrowth 
of injured axons. Sema3A is expressed mainly in the ﬁ  bro-
blasts after injury (De Winter et al 2002), and the speciﬁ  c 
inhibitor of Sema3A clearly promotes the regeneration of 
axons (Kaneko et al 2006). We also demonstrated an addi-
tional example. Repulsive guidance Molecule (RGM), a gly-
cosylphosphatidylinositol (GPI)-anchored membrane-bound 
protein, is another family of guidance molecules important 
for axonal development, which had been shown to navigate 
the optic nerve in the chick tectum to form a topographic map 
(Stahl et al 1990; Monnier et al 2002; for review, Yamashita 
et al 2007). We as well as others elucidated that RGMa is 
also expressed in the injured tissue including astrocytes, 
microglia, oligodendrocytes, and neurons (Schwab et al 
2005; Hata et al 2006). Treatment with RGMa antibody after 
the SCI in a rat promotes axonal regeneration and synapse 
formation, and recovers behavioral function, as evaluated by 
BBB test (Hata et al 2006; Kyoto et al 2007). This data sug-
gests that RGMa is one of the key inhibitory factors for axonal 
regeneration. Morphogens are also candidate molecules that 
inhibit regeneration. We have recently reported that BMP-2/4 
expression is elevated in the lesion of SCI and administration 
of Noggin, a soluble BMP antagonist, promotes regeneration 
of CST (Matsuura et al 2008). BMP is known as a repulsive 
guidance molecule to commissural axons in the developing 
spinal cord (Augsburger et al 1999; Butler and Dodd 2003), Biologics: Targets & Therapy 2008:2(2) 260
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suggesting that similar repulsive factors re-expressed in the 
adult lesion site.
One important issue is that the spinal cord has various 
descending and ascending axons and these have different 
regenerative reaction to therapeutic approaches (Deumens 
et al 2005). In the developing brain, axons in each axon tract 
have different set of receptors for guidance molecules to 
select speciﬁ  c route for the targets. It appears that each tract in 
adult also has speciﬁ  c molecular proﬁ  les for regeneration. For 
example, treatment of Sema3A-inhibitor promotes regenera-
tion of raphespinal tract but not CST (Kaneko et al 2006). It 
was shown that raphespinal axons express neuropilin-1, the 
receptor to mediate repulsive effect of Sema3A. Netrin-1 is 
expressed in oligodendrocytes, cells of central canal, and the 
meninges in adult SCI, and inhibits axonal growth through 
the receptor, Unc5 (Löw et al 2008). Implantation of Netrin-1 
expressing ﬁ  broblasts inhibits the regeneration of rubrospinal 
ﬁ  bers which express Unc5A, but not CGRP-positive noci-
ceptive axons which do not express Unc5. Thus, when the 
effects of the treatment are examined, we should consider 
which axons express receptors for guidance molecules, which 
axons regenerate after treatments, and how the regeneration 
of speciﬁ  c axons contribute to behavioral appearance.
Other targets are the downstream signaling molecules 
of inhibitory cues. Recent reports indicate that the small 
GTP-binding protein Rho and its effectors, ie, ROCK, are 
the key molecules that mediate inhibitory signals for axonal 
growth (for review see Mueller et al 2005; Kubo et al 2007). 
Importantly, Rho is a common downstream molecule of 
many repulsive cues, including RGM (Hata et al 2006), 
myelin-associated proteins through p75 (Yamashita and 
Tohyama 2003), CSPGs (Monnier et al 2003), and members 
of the Semaphorin and Ephrin families (Wahl et al 2000; 
Swiercz et al 2002). Thus, inhibiting the common pathway 
that mediates repulsion is one of the promising targets for 
therapy. Indeed, treatment with ROCK inhibitors, promotes 
axonal regeneration after SCI (Dergham et al 2002; Fournier 
et al 2003; Tanaka et al 2004). Understanding the detailed 
molecular mechanism of the inhibitory signals will reveal 
new targets for therapy.
Many discoveries regarding the role of various molecules 
and their effects in the case of SCI have emerged. This 
indicates that multiple inhibitory factors suppress regenera-
tion. In fact, regeneration can be achieved but not to a great 
extent in each report. The approaches therefore shift to the 
use of a combination of several therapeutic approaches. For 
example, treatment with NT3 and an antibody of myelin-
associated inhibitory proteins (IN-1) (Schnell et al 1994), 
transplantation of fetal spinal cord and neurotrophic factors 
(Bregman et al 1997), chondroitinase ABC and cellular 
transplantation (Fouad et al 2005) etc have succeeded in pro-
moting regeneration to a much greater extent than individual 
therapeutic approaches. Overall, combinational strategies 
that promote the completion of the repair process including 
inﬂ  ammation and scar formation rapidly and in a compact 
manner, excluding the inhibitory factors for regeneration, 
bridging the lesion site, and facilitating the regeneration and 
sprouting of axons, should be considered for designing new 
therapeutic approaches. As the number of possible combina-
tions that should be tested is already very large, greater efforts 
will be required to establish appropriate therapeutic methods. 
The scientiﬁ  c community working on SCI therefore needs to 
be increased and collaborate with each other. Furthermore, 
developmental neuroscientists can rightly contribute to this 
community.
In conclusion, an important aspect gathered from a large 
number of studies is that behavioral recovery after the injury 
by various treatments and methods is well correlated with the 
histological changes that occur in axons, ie axonal regenera-
tion and sprouting. This implies that axonal regeneration and 
sprouting are crucial for behavioral recovery. Thus, promot-
ing axonal elongation and sprouting is now one of the most 
important strategies to be employed for developing a new 
therapeutic method. In this case, basic research on brain 
development will reveal important clues.
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